CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
14 results
Search Results
Now showing 1 - 10 of 14
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?(2021); ;Rodrigo SotoAntoni Torres4Scopus© Citations 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effect of positive end-expiratory pressure on lung injury and haemodynamics during experimental acute respiratory distress syndrome treated with extracorporeal membrane oxygenation and near-apnoeic ventilation(2021) ;Joaquin Araos ;Leyla Alegria ;Aline Garcia ;Pablo CrucesDagoberto SotoScopus© Citations 11 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Outcomes of Sepsis and Septic Shock in Cancer Patients: Focus on Lactate(2021); ;Rodrigo Pérez-Araos ;Fernanda Baus ;Camila MoscosoÁlvaro Salazar<jats:p>The number of oncological patients (OP) admitted to intensive care units (ICU) for sepsis/septic shock has dramatically increased in recent years. The definition of septic shock has been modified, adding hyperlactatemia as a severity biomarker for mortality. However, it remains poorly reported in septic OP. We performed a retrospective analysis from a prospective database of sepsis/septic shock patients admitted to our ICU between September 2017 and September 2019 and followed until day 90. We identified 251 patients and 31.9% had active oncological comorbidity, mainly solid tumor (81.3%). Septic shock criteria were met for 112 (44.6%). Hyperlactatemia was observed in 136 (54.2%) patients and this was associated with a lower survival rate. Overall 90-day mortality was 15.1%. In OP vs. non-OP, hyperlactatemia was more frequent (65% vs. 49.1%, <jats:italic>p</jats:italic> = 0.013) and associated with lower survival (65.4% vs. 85.7%, <jats:italic>p</jats:italic> = 0.046). In OP, poor performance status was also associated with lower survival (HR 7.029 [1.998–24.731], <jats:italic>p</jats:italic> = 0.002) In an adjusted analysis, cancer was associated with lower 90-day survival (HR 2.690 [1.402–5.160], <jats:italic>p</jats:italic> = 0.003). In conclusion, septic OP remains a high mortality risk group in whom lactate levels and performance status could help with better risk stratification.</jats:p>Scopus© Citations 18 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Successful use of mild therapeutic hypothermia as compassionate treatment for severe refractory hypoxemia in COVID-19(2021) ;Pablo Cruces ;Camila Cores ;Daniel Casanova ;Federico PizarroFranco Díaz2Scopus© Citations 13 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Adverse Events of Prone Positioning in Mechanically Ventilated Adults With ARDS(2021) ;Felipe González-Seguel ;Juan José Pinto-Concha ;Nadine Aranis6Scopus© Citations 30 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Successful extracorporeal membrane oxygenation therapy in a child with coronavirus 2019 disease-associated ARDS and chemotherapy for Ewing’s sarcoma(2022) ;Carmen Niño-Taravilla ;Yuri Zuleta-Morales; ;Benigno MontenegroCristian Sotomayor F<jats:p> Most children and adolescents with SARS-CoV-2 infection show no or mild symptoms, but those with medical histories can be susceptible to more severe forms of disease. There are few reported cases of extracorporeal membrane oxygenation (ECMO) in pediatric patients with coronavirus disease 2019 (COVID-19). We present a previously healthy 13-year-old male diagnosed with metastatic Ewing’s sarcoma at the same time as catastrophic acute respiratory distress syndrome due to COVID-19, who was successfully supported by venovenous-ECMO while he received the corresponding chemotherapy protocol. </jats:p><jats:p> ECMO can be used as salvage therapy in oncology pediatric patients with respiratory failure secondary to COVID-19. In addition, successful chemotherapy can be administered while patients are supported on ECMO. </jats:p>3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Extracorporeal Membrane Oxygenation for COVID-19–associated Severe Acute Respiratory Distress Syndrome in Chile: A Nationwide Incidence and Cohort Study(2021) ;Rodrigo A. Diaz; ;José M. Zambrano ;Carolina RuizJuan A. EspinozaScopus© Citations 64 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pediatric Critical Care and COVID-19(2020) ;Sebastián González-Dambrauskas ;Pablo Vásquez-Hoyos ;Anna Camporesi ;Franco Díaz-RubioByron Enrique Piñeres-OlaveScopus© Citations 80 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Continuous prolonged prone positioning in COVID-19-related ARDS: a multicenter cohort study from Chile(2022) ;Rodrigo A. Cornejo ;Jorge Montoya ;Abraham I. J. Gajardo; Leyla Alegría<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Prone positioning is currently applied in time-limited daily sessions up to 24 h which determines that most patients require several sessions. Although longer prone sessions have been reported, there is scarce evidence about the feasibility and safety of such approach. We analyzed feasibility and safety of a continuous prolonged prone positioning strategy implemented nationwide, in a large cohort of COVID-19 patients in Chile.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Retrospective cohort study of mechanically ventilated COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS), conducted in 15 Intensive Care Units, which adhered to a national protocol of continuous prone sessions ≥ 48 h and until PaO<jats:sub>2</jats:sub>:FiO<jats:sub>2</jats:sub> increased above 200 mm Hg. The number and extension of prone sessions were registered, along with relevant physiologic data and adverse events related to prone positioning. The cohort was stratified according to the first prone session duration: Group A, 2–3 days; Group B, 4–5 days; and Group C, > 5 days. Multivariable regression analyses were performed to assess whether the duration of prone sessions could impact safety.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>We included 417 patients who required a first prone session of 4 (3–5) days, of whom 318 (76.3%) received only one session. During the first prone session the main adverse event was grade 1–2 pressure sores in 97 (23.9%) patients; severe adverse events were infrequent with 17 non-scheduled extubations (4.2%). 90-day mortality was 36.2%. Ninety-eight patients (24%) were classified as group C; they exhibited a more severe ARDS at baseline, as reflected by lower PaO<jats:sub>2</jats:sub>:FiO<jats:sub>2</jats:sub> ratio and higher ventilatory ratio, and had a higher rate of pressure sores (44%) and higher 90-day mortality (48%). However, after adjustment for severity and several relevant confounders, prone session duration was not associated with mortality or pressure sores.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Nationwide implementation of a continuous prolonged prone positioning strategy for COVID-19 ARDS patients was feasible. Minor pressure sores were frequent but within the ranges previously described, while severe adverse events were infrequent. The duration of prone session did not have an adverse effect on safety.</jats:p> </jats:sec>Scopus© Citations 17 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Cardiac function in critically ill patients with severe COVID: A prospective cross-sectional study in mechanically ventilated patients(2022) ;Emilio Daniel Valenzuela ;Pablo Mercado ;Ronald Pairumani ;Juan Nicolás MedelEdward PetruskaScopus© Citations 6 64